Immix Biopharma - Reaffirmed long-term focus on outpatient CAR-T
Immix Biopharma is continuing its strategic pivot towards exploring non-traditional indications for its CAR-T asset, NXC-201, leading with...
298 Views
Immix Biopharma - Marching towards US clinical trials for NXC-201
Immix Biopharma is closer to dosing its first US patient for lead CAR-T asset NXC-201, with the appointment of the Memorial Sloan Kettering Cancer...
267 Views
Immix Biopharma - 2023 recap with a preview of active year ahead
IMMX has shared a 12-month recap, capturing key clinical and regulatory events from 2023, setting the stage for an active 2024. Its lead CAR-T...
199 Views
Immix Biopharma - Updates galore: NXC-201 ODD (EU) and raise
Immix Biopharma has released back-to-back updates, including EU orphan drug designation (ODD) for its lead CAR-T asset NXC-201, addressing amyloid...
258 Views
Immix Biopharma - Increased legroom following common-only raise
Immix Biopharma has announced a $15m (gross), fully underwritten equity issue. The company will use the proceeds to fund clinical trials for lead...
173 Views